VIP(6-28)(human, rat, porcine, bovine) |
Catalog No.GC37910
One-Click Copy Product Info
|
VIP(6-28)(human, rat, porcine, bovine) is a potent vasoactive intestinal peptide (VIP) antagonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 69698-54-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
VIP(6-28)(human, rat, porcine, bovine) is a potent vasoactive intestinal peptide (VIP) antagonist. In neuron-rich culture systems, VIP(6-28)(human, rat, porcine, bovine) inhibits VIP-induced increases in cAMP and VIP-PHI mRNA[1].
VIP(6-28)(human, rat, porcine, bovine) (100μM; 48h) inhibited the VIP‑stimulated increase in VIP–PHI mRNA by 60%, while having no effect on basal VIP–PHI mRNA levels on its own in neonatal dissociated rat SCGs[1]. In short‑term cultures of adult rat SCGs, VIP(6-28)(human, rat, porcine, bovine) at concentrations of 10, 30, or 100μM for 1h inhibited the 10μM VIP‑induced elevation of cAMP levels by 52%, 64%, and 81%, respectively[1]. In human odontoblast-like cells, VIP(6-28)(human, rat, porcine, bovine) reduced the VIP-induced cAMP elevation to 66.4% and 55.8% of control at 10nM and 100nM for 2min, respectively[2]. VIP(6-28)(human, rat, porcine, bovine) (5µM; 48h) antagonized the VIP-induced promotion of follicle activation in rat ovarian follicles[3].
References:
[1] Mohney RP, Zigmond RE. Vasoactive intestinal peptide enhances its own expression in sympathetic neurons after injury. J Neurosci. 1998;18(14):5285-5293.
[2] Kitayama E, Kimura M, Ouchi T, Furusawa M, Shibukawa Y. Functional Expression of IP, 5-HT4, D1, A2A, and VIP Receptors in Human Odontoblast Cell Line. Biomolecules. 2023;13(6):879.
[3] Li S, Fan Q, Xie Y, et al. VIP activates primordial follicles of rat through ERK-mTOR pathway in tissue culture. Reproduction. 2019;157(5):475-484.
| Cell experiment [1]: | |
Cell lines | Neonatal dissociated rat SCGs |
Preparation Method | Neuron-enriched cultures derived from neonatal dissociated SCG were isolated and stimulated with VIP (10μM) in the presence or absence of VIP(6-28)(human, rat, porcine, bovine) (100μM). Forty-eight hours later, levels of VIP–PHI mRNA were measured by Northern blot analysis. |
Reaction Conditions | 100μM; 48h |
Applications | VIP(6-28)(human, rat, porcine, bovine) did not affect VIP–PHI mRNA levels by itself, but it did inhibit, by 60%, the VIP-stimulated increase in VIP–PHI mRNA. |
References: | |
| Cas No. | 69698-54-0 | SDF | |
| Formula | C126H207N37O34S | M.Wt | 2816.28 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 355.1 μL | 1.7754 mL | 3.5508 mL |
| 5 mM | 71 μL | 355.1 μL | 710.2 μL |
| 10 mM | 35.5 μL | 177.5 μL | 355.1 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)